These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 21536468)

  • 21. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
    Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
    Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absolute fracture risk assessment using lumbar spine and femoral neck bone density measurements: derivation and validation of a hybrid system.
    Leslie WD; Lix LM;
    J Bone Miner Res; 2011 Mar; 26(3):460-7. PubMed ID: 20839285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment.
    Watts NB; Miller PD; Kohlmeier LA; Sebba A; Chen P; Wong M; Krohn K
    J Bone Miner Res; 2009 Jun; 24(6):1125-31. PubMed ID: 19113918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Velaglucerase alfa: a new option for Gaucher disease treatment.
    Zimran A
    Drugs Today (Barc); 2011 Jul; 47(7):515-29. PubMed ID: 22013559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy.
    Yao S; McCarthy PL; Dunford LM; Roy DM; Brown K; Paplham P; Syta M; Lamonica D; Smiley S; Battiwalla M; Padmanabhan S; Hahn T
    Bone Marrow Transplant; 2008 Feb; 41(4):393-8. PubMed ID: 17994116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bone mineral accrual in osteopenic and non-osteopenic girls with idiopathic scoliosis during bracing treatment.
    Qiu Y; Sun X; Cheng JC; Zhu F; Li W; Zhu Z; Wang B; Yu Y
    Spine (Phila Pa 1976); 2008 Jul; 33(15):1682-9. PubMed ID: 18594461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.
    Lange U; Teichmann J; Müller-Ladner U; Strunk J
    Rheumatology (Oxford); 2005 Dec; 44(12):1546-8. PubMed ID: 16263785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disease activity and disability but probably not glucocorticoid treatment predicts loss in bone mineral density in women with early rheumatoid arthritis.
    Book C; Karlsson M; Akesson K; Jacobsson L
    Scand J Rheumatol; 2008; 37(4):248-54. PubMed ID: 18612924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy.
    Cino M; Greenberg GR
    Am J Gastroenterol; 2002 Apr; 97(4):915-21. PubMed ID: 12003427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
    Ryan CW; Huo D; Stallings JW; Davis RL; Beer TM; McWhorter LT
    Urology; 2007 Jul; 70(1):122-6. PubMed ID: 17656221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
    J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Associations of genetic lactase non-persistence and sex with bone loss in young adulthood.
    Laaksonen MM; Impivaara O; Sievänen H; Viikari JS; Lehtimäki TJ; Lamberg-Allardt CJ; Kärkkäinen MU; Välimäki M; Heikkinen J; Kröger LM; Kröger HP; Jurvelin JS; Kähönen MA; Raitakari OT;
    Bone; 2009 May; 44(5):1003-9. PubMed ID: 19168163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AI-related BMD variation in actual practice conditions: A prospective cohort study.
    Rodríguez-Sanz M; Prieto-Alhambra D; Servitja S; Garcia-Giralt N; Garrigos L; Rodriguez-Morera J; Albanell J; Martínez-García M; González I; Diez-Perez A; Tusquets I; Nogués X
    Endocr Relat Cancer; 2016 Apr; 23(4):303-12. PubMed ID: 26911377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.
    Mistry PK; Weinreb NJ; Kaplan P; Cole JA; Gwosdow AR; Hangartner T
    Blood Cells Mol Dis; 2011 Jan; 46(1):66-72. PubMed ID: 21112800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone density changes with enzyme therapy for Gaucher disease.
    Lebel E; Dweck A; Foldes AJ; Golowa Y; Itzchaki M; Zimran A; Elstein D
    J Bone Miner Metab; 2004; 22(6):597-601. PubMed ID: 15490271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation.
    Tauchmanovà L; Ricci P; Serio B; Lombardi G; Colao A; Rotoli B; Selleri C
    J Clin Endocrinol Metab; 2005 Feb; 90(2):627-34. PubMed ID: 15546907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience.
    Zimran A; Altarescu G; Philips M; Attias D; Jmoudiak M; Deeb M; Wang N; Bhirangi K; Cohn GM; Elstein D
    Blood; 2010 Jun; 115(23):4651-6. PubMed ID: 20299511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term effect of exemestane therapy on bone mineral density supported by bisphosphonates: Results of 5-year adjuvant treatment in postmenopausal women with early-stage breast cancer.
    Hirano A; Inoue H; Ogura K; Hattori A; Yukawa H; Sakaguchi S; Matsuoka A; Tanaka N; Kodera A; Kamimura M; Naritaka Y; Shimizu T
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e238-e242. PubMed ID: 29932305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease.
    Pastores GM; Turkia HB; Gonzalez DE; Ida H; Tantawy AA; Qin Y; Qiu Y; Dinh Q; Zimran A
    Blood Cells Mol Dis; 2016 Jul; 59():37-43. PubMed ID: 27282565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.